Literature DB >> 17382107

Treatment with rituximab in benign and malignant hematologic disorders in children.

Lisa B Giulino1, James B Bussel, Ellis J Neufeld.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17382107      PMCID： PMC2586083          DOI： 10.1016/j.jpeds.2006.12.038

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  80 in total

1.  Lymphoproliferative syndrome in an infant after stem cell transplantation: successful therapy with T-lymphocytes and anti-CD20 monoclonal antibodies.

Authors:  D K Stachel; I Schmid; F Schuster; M Stehr; F A Baumeister; J Müller-Höcker
Journal:  Med Pediatr Oncol       Date:  2000-11

2.  Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and Rituximab.

Authors:  S Skoda-Smith; V K Douglas; P Mehta; J Graham-Pole; J R Wingard
Journal:  Bone Marrow Transplant       Date:  2001-02       Impact factor: 5.483

3.  Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs.

Authors:  S Alas; B Bonavida
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

4.  Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

Authors:  J C Byrd; T Murphy; R S Howard; M S Lucas; A Goodrich; K Park; M Pearson; J K Waselenko; G Ling; M R Grever; A J Grillo-Lopez; J Rosenberg; L Kunkel; I W Flinn
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

5.  Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.

Authors:  S Alas; C Emmanouilides; B Bonavida
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

6.  Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.

Authors:  P McLaughlin; F B Hagemeister; M A Rodriguez; A H Sarris; O Pate; A Younes; M S Lee; N H Dang; J E Romaguera; A H Preti; N McAda; F Cabanillas
Journal:  Semin Oncol       Date:  2000-12       Impact factor: 4.929

7.  Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia.

Authors:  M Zecca; P De Stefano; B Nobili; F Locatelli
Journal:  Blood       Date:  2001-06-15       Impact factor: 22.113

8.  Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.

Authors:  Mary Mathias; Kate Khair; Ian Hann; Ri Liesner
Journal:  Br J Haematol       Date:  2004-05       Impact factor: 6.998

9.  Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients.

Authors:  Sigbjørn Berentsen; Elling Ulvestad; Bjørn Tore Gjertsen; Henrik Hjorth-Hansen; Ruth Langholm; Håvar Knutsen; Waleed Ghanima; Fuad Victor Shammas; Geir E Tjønnfjord
Journal:  Blood       Date:  2003-12-30       Impact factor: 22.113

10.  The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.

Authors:  Nichola Cooper; Roberto Stasi; Susanna Cunningham-Rundles; Michael A Feuerstein; John P Leonard; Sergio Amadori; James B Bussel
Journal:  Br J Haematol       Date:  2004-04       Impact factor: 6.998
View more
  16 in total

1.  Rituximab in steroid refractory autoimmune hemolytic anemia.

Authors:  Nitin Gupta; Sanjeev Sharma; Tulika Seth; Pravas Mishra; Manoranjan Mahapatra; Suman Kumar; Rajan Kapoor; Narendra Agarwal
Journal:  Indian J Pediatr       Date:  2011-08-10       Impact factor: 1.967

Review 2.  Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells.

Authors:  Carol H Miao
Journal:  Expert Rev Hematol       Date:  2010-08       Impact factor: 2.929

Review 3.  B-cells and humoral immunity in multiple sclerosis. Implications for therapy.

Authors:  Sangjin Oh; Cornelia Cudrici; Takahiro Ito; Horea Rus
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 4.  Childhood immune thrombocytopenia: Clinical presentation and management.

Authors:  Mohamed El Faki Osman
Journal:  Sudan J Paediatr       Date:  2012

5.  Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab.

Authors:  Kousaku Matsubara; Yoshiyuki Takahashi; Akira Hayakawa; Fumiko Tanaka; Hisaya Nakadate; Michio Sakai; Naoko Maeda; Toshiaki Oka; Eiichi Ishii; Fumio Bessho; Tsuyoshi Morimoto; Hiroaki Goto; Yoshiko Hashii; Naoki Hatakeyama; Akira Shirahata; Masue Imaizumi
Journal:  Int J Hematol       Date:  2014-03-08       Impact factor: 2.490

6.  B cell depletion for autoimmune diseases in paediatric patients.

Authors:  Annette F Jansson; Claudia Sengler; Jasmin Kuemmerle-Deschner; Bernd Gruhn; A Birgitta Kranz; Hartwig Lehmann; Daniela Kleinert; Lars Pape; Hermann J Girschick; Ivan Foeldvari; Dieter Haffner; Johannes P Haas; Dagmar Moebius; Dirk Foell; Joachim Peitz; Veit Grote
Journal:  Clin Rheumatol       Date:  2010-12-01       Impact factor: 2.980

Review 7.  The long-term impact of rituximab for childhood immune thrombocytopenia.

Authors:  Nichola Cooper; James B Bussel
Journal:  Curr Rheumatol Rep       Date:  2010-04       Impact factor: 4.592

8.  Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS).

Authors:  V Koneti Rao; Susan Price; Katie Perkins; Patricia Aldridge; Jean Tretler; Joie Davis; Janet K Dale; Fred Gill; Kip R Hartman; Linda C Stork; David J Gnarra; Lakshmanan Krishnamurti; Peter E Newburger; Jennifer Puck; Thomas Fleisher
Journal:  Pediatr Blood Cancer       Date:  2009-07       Impact factor: 3.167

9.  Successful treatment with rituximab of an infant with refractory autoimmune hemolytic anemia.

Authors:  Kunihiko Moriya; Tetsuro Matsuhashi; Masaei Onuma; Hidetaka Niizuma; Takeshi Rikiishi; Hiroshi Asada; Jun Suzuki; Yoji Sasahara; Shigeo Kure
Journal:  Int J Hematol       Date:  2013-05-24       Impact factor: 2.490

Review 10.  Targeting the B cell in vasculitis.

Authors:  Michael Walsh; David Jayne
Journal:  Pediatr Nephrol       Date:  2008-10-18       Impact factor: 3.714
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.